IDEXX Laboratories, Inc. vs Slide Insurance Holdings Inc. Common Stock — how do they compare? IDEXX Laboratories, Inc. trades at $532.96 (market cap $40.99B), while Slide Insurance Holdings Inc. Common Stock trades at $25.84 (market cap $2.98B). The key difference: IDEXX Laboratories, Inc. is far larger — about 13.8× Slide Insurance Holdings Inc. Common Stock's market cap, and Slide Insurance Holdings Inc. Common Stock pays a 1.1% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 47 Days and Slide Insurance Holdings Inc. Common Stock for 0 Days on average.
| IDXX | SLDE | |
|---|---|---|
Market Cap | $40.99B | $2.98B |
Volume | 445,410 | 927,183 |
Sector | Health | Financials |
52-Week High | $766.68 | $26.48 |
52-Week Low | $504.70 | $14.38 |
Typical Hold Time | 47 Days | 0 Days |
Enterprise Value | $41.89B | $1.78B |
Dividend Yield | — | 1.1% |
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $529.01, up 0.97% with strong fundamental performance including 25.03% net income margin and consistent earnings beats. The stock shows neutral technical signals with support at $518 and resistance at $528. Recent acquisitions like CoVetAI and diagnostic platform expansions demonstrate strategic growth initiatives. Revenue grew from $3.9B in 2024 to $4.3B in 2025 with profit margins expanding to 24.61%.
Outlook remains positive with 56.5% analyst buy ratings and $665 consensus price target representing 25.7% upside. Key risks include FX headwinds and weaker U.S. vet visits, but strong recurring revenue and diagnostic innovation pipeline support long-term growth framework. The company's premium valuation (P/E 36.56) reflects market confidence in sustained profitability.
SLDE trades at $25.50, down slightly (-0.12%) on the day, with strong fundamental metrics including a P/E of 6.16 and net income margin of 40.02%. The company has consistently beaten earnings expectations in recent quarters, with Q3 2026 results scheduled for October 27, 2026. Revenue growth from $1.16B in 2025 to projected $1.4B in 2026 demonstrates solid business momentum, supported by expanded insurance offerings in key markets.
The stock presents attractive value with strong profitability and analyst support (80% buy ratings), though hurricane exposure in Florida remains a key risk. Current price sits near consensus target of $25.00, suggesting limited near-term upside but solid fundamentals for long-term investors. Management's share repurchase program and dividend initiation provide additional shareholder value support.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →Slide Insurance Holdings, Inc. is a technology-enabled insurance company based in Florida that underwrites coastal specialty personal lines insurance, including homeowners and condominium unit owner policies, and also provides reinsurance and insurance agency services.
Read more on SLDE →